Skip to main content
Top
Published in: Drugs & Aging 9/2005

01-09-2005 | Review Article

Postural Instability and Consequent Falls and Hip Fractures Associated with Use of Hypnotics in the Elderly

A Comparative Review

Authors: Professor Hervé Allain, Danièle Bentué-Ferrer, Elisabeth Polard, Yvette Akwa, Alain Patat

Published in: Drugs & Aging | Issue 9/2005

Login to get access

Abstract

The aim of this review is to establish the relationship between treatment with hypnotics and the risk of postural instability and as a consequence, falls and hip fractures, in the elderly.
A review of the literature was performed through a search of the MEDLINE, Ingenta and PASCAL databases from 1975 to 2005. We considered as hypnotics only those drugs approved for treating insomnia, i.e. some benzodiazepines and the more recently launched ‘Z’-compounds, i.e. zopiclone, zolpidem and zaleplon.
Large-scale surveys consistently report increases in the frequency of falls and hip fractures when hypnotics are used in the elderly (2-fold risk). Benzodiazepines are the major class of hypnotics involved in this context; falls and fractures in patients taking Z-compounds are less frequently reported, and in this respect, zolpidem is considered as at risk in only one study. It is important to note, however, that drug adverse effect relationships are difficult to establish with this type of epidemiological data-mining. On the other hand, data obtained in laboratory settings, where confounding factors can be eliminated, prove that benzodiazepines are the most deleterious hypnotics at least in terms of their effects on body sway. Z-compounds are considered safer, probably because of their pharmacokinetic properties as well as their selective pharmacological activities at benzodiazepine-1 (BZ1) receptors. The effects of hypnotics on balance, gait and equilibrium are the consequence of differential negative impacts on vigilance and cognitive functions, and are highly dose- and time-dependent. Z-compounds have short half-lives and have less cognitive and residual effects than older medications.
Some practical rules need to be followed when prescribing hypnotics in order to prevent falls and hip fractures as much as possible in elderly insomniacs, whether institutionalised or not. These are: (i) establish a clear diagnosis of the sleep disorder; (ii) take into account chronic conditions leading to balance and gait difficulties (motor and cognitive status); (iii) search for concomitant prescription of psychotropics and sedatives; (iv) use half the recommended adult dosage; and (v) declare any adverse effect to pharmacovigilance centres. Comparative pharmacovigilance studies focused on the impact of hypnotics on postural stability are very much needed.
Literature
1.
go back to reference MacDonald JB, MacDonald T. Nocturnal femoral fracture and continuing widespread use of barbiturate hypnotics. BMJ 1977; 2: 483–6PubMedCrossRef MacDonald JB, MacDonald T. Nocturnal femoral fracture and continuing widespread use of barbiturate hypnotics. BMJ 1977; 2: 483–6PubMedCrossRef
2.
go back to reference Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363–9PubMedCrossRef Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363–9PubMedCrossRef
3.
5.
go back to reference Malmivaara A, Heliovaara M, Knekt P, et al. Risk factors for injurious falls leading to hospitalization or death in a cohort of 19,500 adults. Am J Epidemiol 1993; 138: 384–94PubMed Malmivaara A, Heliovaara M, Knekt P, et al. Risk factors for injurious falls leading to hospitalization or death in a cohort of 19,500 adults. Am J Epidemiol 1993; 138: 384–94PubMed
6.
go back to reference Coming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. Epidemiol Rev 1997; 19: 244–57CrossRef Coming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. Epidemiol Rev 1997; 19: 244–57CrossRef
7.
go back to reference Kreisfeld R. The growing problem of elderly falls. Injury Issues Monitor 2000; 20: 5–6 Kreisfeld R. The growing problem of elderly falls. Injury Issues Monitor 2000; 20: 5–6
8.
go back to reference Kannus P, Niemi S, Palvanen M, et al. Continuously increasing number and incidence of fall induced, fracture associated, spinal cord injuries in elderly persons. Arch Intern Med 2000; 160: 2145–9PubMedCrossRef Kannus P, Niemi S, Palvanen M, et al. Continuously increasing number and incidence of fall induced, fracture associated, spinal cord injuries in elderly persons. Arch Intern Med 2000; 160: 2145–9PubMedCrossRef
9.
go back to reference Lawlor DA, Patel R, Ebrahim S. Association between falls in elderly women and chronic diseases and drug use: cross sectional study. BMJ 2003; 327: 1–6 Lawlor DA, Patel R, Ebrahim S. Association between falls in elderly women and chronic diseases and drug use: cross sectional study. BMJ 2003; 327: 1–6
10.
go back to reference Stenbacka M, Jansson B, Leifman A, et al. Association between use of sedative or hypnotics, alcohol consumption, or other risk factors and a single injurious fall or multiple injurious falls; a longitudinal general population study. Alcohol 2002; 28: 9–16PubMedCrossRef Stenbacka M, Jansson B, Leifman A, et al. Association between use of sedative or hypnotics, alcohol consumption, or other risk factors and a single injurious fall or multiple injurious falls; a longitudinal general population study. Alcohol 2002; 28: 9–16PubMedCrossRef
11.
go back to reference Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 1998; 12: 43–53PubMedCrossRef Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 1998; 12: 43–53PubMedCrossRef
12.
go back to reference Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324: 1691–8PubMedCrossRef Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324: 1691–8PubMedCrossRef
13.
go back to reference Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17: 825–37PubMedCrossRef Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17: 825–37PubMedCrossRef
14.
go back to reference Leipzig R, Cumming R, Tinetti M. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999; 47: 30–9PubMed Leipzig R, Cumming R, Tinetti M. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999; 47: 30–9PubMed
15.
go back to reference Lord SR, Anstey KJ, Williams P, et al. Psychoactive medication use, sensorimotor function and falls in older women. Br J Clin Pharmacol 1995; 39: 227–34PubMedCrossRef Lord SR, Anstey KJ, Williams P, et al. Psychoactive medication use, sensorimotor function and falls in older women. Br J Clin Pharmacol 1995; 39: 227–34PubMedCrossRef
16.
go back to reference Sanger DJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004; 1: 9–15CrossRef Sanger DJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004; 1: 9–15CrossRef
17.
go back to reference Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004; 43: 227–38PubMedCrossRef Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004; 43: 227–38PubMedCrossRef
19.
go back to reference Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997; 278: 2170–7PubMedCrossRef Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997; 278: 2170–7PubMedCrossRef
20.
go back to reference Olubodun JO, Ochs HR, von Moltke LL, et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol 2003; 56: 297–304PubMedCrossRef Olubodun JO, Ochs HR, von Moltke LL, et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol 2003; 56: 297–304PubMedCrossRef
21.
go back to reference Panneman MJ, Goettsch WG, Kramarz P, et al. The costs of benzodiazepine-associated hospital-treated fall injuries in the EU: a Pharmo study. Drugs Aging 2003; 20: 833–9PubMedCrossRef Panneman MJ, Goettsch WG, Kramarz P, et al. The costs of benzodiazepine-associated hospital-treated fall injuries in the EU: a Pharmo study. Drugs Aging 2003; 20: 833–9PubMedCrossRef
22.
go back to reference Le Dictionnaire Vidal. 81st ed. Paris: Vidal, 2005 Le Dictionnaire Vidal. 81st ed. Paris: Vidal, 2005
23.
go back to reference Ensrud KE, Blackwell TL, Mangione CM, et al., for the Study of Osteoporotic Fractures Research Group. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002; 50: 1629–37PubMedCrossRef Ensrud KE, Blackwell TL, Mangione CM, et al., for the Study of Osteoporotic Fractures Research Group. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002; 50: 1629–37PubMedCrossRef
24.
go back to reference Chaimowicz F, Ferreira TJXM, Miguel DFA. Use of psychoactive drugs and related falls among older people living in a community in Brazil. Rev Saude Publica 2002; 34: 631–5CrossRef Chaimowicz F, Ferreira TJXM, Miguel DFA. Use of psychoactive drugs and related falls among older people living in a community in Brazil. Rev Saude Publica 2002; 34: 631–5CrossRef
25.
go back to reference Frels C, Williams P, Narayanan S, et al. Iatrogenic causes of falls in hospitalised elderly patients: a case-control study. Postgrad Med 2002; 78: 487–9CrossRef Frels C, Williams P, Narayanan S, et al. Iatrogenic causes of falls in hospitalised elderly patients: a case-control study. Postgrad Med 2002; 78: 487–9CrossRef
26.
go back to reference Pierfitte C, Macouillard G, Thicoipe M, et al. Benzodiazepines and hip fractures in elderly people: case control study. BMJ 2001; 322: 704–8PubMedCrossRef Pierfitte C, Macouillard G, Thicoipe M, et al. Benzodiazepines and hip fractures in elderly people: case control study. BMJ 2001; 322: 704–8PubMedCrossRef
27.
go back to reference Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and risk of hip fracture. JAMA 1989; 262: 3303–7PubMedCrossRef Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and risk of hip fracture. JAMA 1989; 262: 3303–7PubMedCrossRef
28.
go back to reference Allain H, Delahaye C, Le Coz F, et al. Post-marketing surveillance of zopiclone in insomnia. Sleep 1991; 14: 408–13PubMed Allain H, Delahaye C, Le Coz F, et al. Post-marketing surveillance of zopiclone in insomnia. Sleep 1991; 14: 408–13PubMed
29.
go back to reference Wang PS, Bohn RL, Glynn RJ, et al. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001; 49: 1685–90PubMedCrossRef Wang PS, Bohn RL, Glynn RJ, et al. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001; 49: 1685–90PubMedCrossRef
30.
go back to reference Bailey L, Ward M, Musa MN. Clinical pharmacokinetics of benzodiazepines. J Clin Pharmacol 1994; 34: 804–11PubMed Bailey L, Ward M, Musa MN. Clinical pharmacokinetics of benzodiazepines. J Clin Pharmacol 1994; 34: 804–11PubMed
31.
go back to reference Greenblatt DJ, Divoll M, Abernethy DR, et al. Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1983; 8: 233–52PubMedCrossRef Greenblatt DJ, Divoll M, Abernethy DR, et al. Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1983; 8: 233–52PubMedCrossRef
32.
go back to reference Holbrook AM, Crowter R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000; 162: 225–33PubMed Holbrook AM, Crowter R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000; 162: 225–33PubMed
33.
go back to reference Kyriakopolous AA, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of lorazepam: a review. J Clin Psychiatry 1978; 39: 16–23 Kyriakopolous AA, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of lorazepam: a review. J Clin Psychiatry 1978; 39: 16–23
34.
go back to reference Luscombe DK. Lormetazepam-plasma concentrations in volunteers following sublingual and oral dosing. Psychopharmacology 1984; 1: 99–104PubMed Luscombe DK. Lormetazepam-plasma concentrations in volunteers following sublingual and oral dosing. Psychopharmacology 1984; 1: 99–104PubMed
35.
go back to reference Seyberth HW. Pharmacokinetics and biotransformation of the new benzodiazepine, lormetazepam, in man: III. Repeated administration and transfer to neonates via breast milk. Eur J Clin Pharmacol 1983; 24: 139–40PubMedCrossRef Seyberth HW. Pharmacokinetics and biotransformation of the new benzodiazepine, lormetazepam, in man: III. Repeated administration and transfer to neonates via breast milk. Eur J Clin Pharmacol 1983; 24: 139–40PubMedCrossRef
36.
go back to reference Humpel M, Illi V, Milius W, et al. The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans: I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C. Eur J Drug Metab Pharmacokinet 1979; 4: 237–43PubMedCrossRef Humpel M, Illi V, Milius W, et al. The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans: I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C. Eur J Drug Metab Pharmacokinet 1979; 4: 237–43PubMedCrossRef
37.
go back to reference Humpel M, Nieuweboer B, Milius W, et al. Kinetics and bio-transformation of lormetazepam: II. Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect. Clin Pharmacol Ther 1980; 28: 673–9PubMedCrossRef Humpel M, Nieuweboer B, Milius W, et al. Kinetics and bio-transformation of lormetazepam: II. Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect. Clin Pharmacol Ther 1980; 28: 673–9PubMedCrossRef
38.
go back to reference Hildebrand M, Hellstern A, Humpel M, et al. Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. Eur J Drug Metab Pharmacokinet 1990; 15: 19–26PubMedCrossRef Hildebrand M, Hellstern A, Humpel M, et al. Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. Eur J Drug Metab Pharmacokinet 1990; 15: 19–26PubMedCrossRef
39.
go back to reference Pakes GE, Brogden RN, Heel RC, et al. Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs 1981; 22: 81–110PubMedCrossRef Pakes GE, Brogden RN, Heel RC, et al. Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs 1981; 22: 81–110PubMedCrossRef
40.
go back to reference Kroboth PD, Juhl RP. New drug evaluations: triazolam. Drug Intell Clin Pharm 1983; 17: 495–500PubMed Kroboth PD, Juhl RP. New drug evaluations: triazolam. Drug Intell Clin Pharm 1983; 17: 495–500PubMed
41.
go back to reference Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000; 59: 865–89PubMedCrossRef Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000; 59: 865–89PubMedCrossRef
42.
go back to reference Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 2005; 19: 65–89PubMedCrossRef Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 2005; 19: 65–89PubMedCrossRef
43.
go back to reference Lee YJ. Overview of the therapeutic management of insomnia with zolpidem. CNS Drugs 2004; 1: 17–23CrossRef Lee YJ. Overview of the therapeutic management of insomnia with zolpidem. CNS Drugs 2004; 1: 17–23CrossRef
44.
go back to reference Noble S, Langtry HD, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998; 55: 277–302PubMedCrossRef Noble S, Langtry HD, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998; 55: 277–302PubMedCrossRef
45.
go back to reference Montplaisir J, Hawa R, Moller H, et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 2003; 18: 29–38PubMedCrossRef Montplaisir J, Hawa R, Moller H, et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 2003; 18: 29–38PubMedCrossRef
46.
go back to reference Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000; 60: 413–45PubMedCrossRef Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000; 60: 413–45PubMedCrossRef
47.
go back to reference Barbera J, Shapiro C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 2005; 28: 301–18PubMedCrossRef Barbera J, Shapiro C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 2005; 28: 301–18PubMedCrossRef
48.
go back to reference Heydorn WE. Zaleplon: a review of a novel sedative hypnotic used in the treatment of insomnia. Expert Opin Investig Drugs 2000; 9: 841–58PubMedCrossRef Heydorn WE. Zaleplon: a review of a novel sedative hypnotic used in the treatment of insomnia. Expert Opin Investig Drugs 2000; 9: 841–58PubMedCrossRef
49.
go back to reference Herings RM, Stricker BH, De Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995; 155: 1801–7PubMedCrossRef Herings RM, Stricker BH, De Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995; 155: 1801–7PubMedCrossRef
50.
go back to reference Slemenda C. Prevention of hip fractures: risk factor modification. Am J Med 1997; 103: 65–73CrossRef Slemenda C. Prevention of hip fractures: risk factor modification. Am J Med 1997; 103: 65–73CrossRef
51.
52.
go back to reference Darcourt G, Pringuey D, Salliere D, et al. The safety and tolerability of zolpidem: an update. J Psychopharmacol 1999; 13: 81–93PubMedCrossRef Darcourt G, Pringuey D, Salliere D, et al. The safety and tolerability of zolpidem: an update. J Psychopharmacol 1999; 13: 81–93PubMedCrossRef
53.
go back to reference Hajak G, Bandelow B. Safety tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16,944 cases. Int Clin Psychopharmacol 1998; 13: 157–67PubMedCrossRef Hajak G, Bandelow B. Safety tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16,944 cases. Int Clin Psychopharmacol 1998; 13: 157–67PubMedCrossRef
54.
go back to reference Allain H, Monti J. General safety of zolpidem: safety in elderly, overdose and rebound effects. Eur Psychiatry 1997; 12Suppl. 1: 21s–9sCrossRef Allain H, Monti J. General safety of zolpidem: safety in elderly, overdose and rebound effects. Eur Psychiatry 1997; 12Suppl. 1: 21s–9sCrossRef
55.
go back to reference Eto F, Saotome I, Furuichi T, et al. Effects of long-term use of benzodiazepines on gait and standing balance in the elderly. Ann N Y Acad Sci 1998; 860: 543–5PubMedCrossRef Eto F, Saotome I, Furuichi T, et al. Effects of long-term use of benzodiazepines on gait and standing balance in the elderly. Ann N Y Acad Sci 1998; 860: 543–5PubMedCrossRef
56.
go back to reference Cutson TM, Gray SL, Hughes MA, et al. Effect of a single dose of diazepam on balance measures in older people. J Am Geriatr Soc 1997; 45: 435–40PubMed Cutson TM, Gray SL, Hughes MA, et al. Effect of a single dose of diazepam on balance measures in older people. J Am Geriatr Soc 1997; 45: 435–40PubMed
57.
go back to reference Robin DW, Hasan SS, Edeki T, et al. Increased baseline sway contributes to increased losses of balance in older people following triazolam. J Am Geriatr Soc 1996; 44: 300–4PubMed Robin DW, Hasan SS, Edeki T, et al. Increased baseline sway contributes to increased losses of balance in older people following triazolam. J Am Geriatr Soc 1996; 44: 300–4PubMed
58.
go back to reference Patat A. Clinical pharmacology of psychotropic drugs. Hum Psychopharmacol Clin Exp 2000; 15: 361–87CrossRef Patat A. Clinical pharmacology of psychotropic drugs. Hum Psychopharmacol Clin Exp 2000; 15: 361–87CrossRef
59.
go back to reference Bourin M, Briley M. Sedation, an unpleasant, undesirable and potentially dangerous side effect of many psychotropic drugs. Hum Psychopharmacol Clin Exp 2004; 19: 135–9CrossRef Bourin M, Briley M. Sedation, an unpleasant, undesirable and potentially dangerous side effect of many psychotropic drugs. Hum Psychopharmacol Clin Exp 2004; 19: 135–9CrossRef
60.
go back to reference Swift CG. Postural instability as a measure of sedative drug response. Br J Clin Pharmacol 1984; 18: 87–90CrossRef Swift CG. Postural instability as a measure of sedative drug response. Br J Clin Pharmacol 1984; 18: 87–90CrossRef
61.
go back to reference McClelland GR. Body sway and the effects of psychoactive drugs: a review. Hum Psychopharmacol Clin Exp 1989; 4: 3–14CrossRef McClelland GR. Body sway and the effects of psychoactive drugs: a review. Hum Psychopharmacol Clin Exp 1989; 4: 3–14CrossRef
62.
go back to reference Patat A, Foulhoux P. Effects on postural sway of various benzodiazepine tranquillizers. Br J Clin Pharmacol 1985; 2: 9–16CrossRef Patat A, Foulhoux P. Effects on postural sway of various benzodiazepine tranquillizers. Br J Clin Pharmacol 1985; 2: 9–16CrossRef
63.
go back to reference Patat A, Foulhoux P, Klein MJ. Etude des effets résiduels sur l’equilibre de trois hypnotiques (loprazolam, flunitrazépam, triazolam) appréciés par l’analyse spectrale des oscillations posturales [in French]. Thérapie 1986; 41: 443–7PubMed Patat A, Foulhoux P, Klein MJ. Etude des effets résiduels sur l’equilibre de trois hypnotiques (loprazolam, flunitrazépam, triazolam) appréciés par l’analyse spectrale des oscillations posturales [in French]. Thérapie 1986; 41: 443–7PubMed
64.
go back to reference Patat A, Klein MJ, Jones RW. Acute effects on psychomotor performance of binedaline alone and with alcohol. Methods Find Exp Clin Pharmacol 1988; 10: 393–9PubMed Patat A, Klein MJ, Jones RW. Acute effects on psychomotor performance of binedaline alone and with alcohol. Methods Find Exp Clin Pharmacol 1988; 10: 393–9PubMed
65.
go back to reference Patat A, Perault MC, Vandel B, et al. Assessment of the interaction between a partial antagonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory in healthy volunteers. J Psychopharmacol 1995; 2: 91–101CrossRef Patat A, Perault MC, Vandel B, et al. Assessment of the interaction between a partial antagonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory in healthy volunteers. J Psychopharmacol 1995; 2: 91–101CrossRef
66.
go back to reference Allain H, Patat A, Le Coz F, et al. Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur J Psychiatry 1995; 10: 129s–35sCrossRef Allain H, Patat A, Le Coz F, et al. Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur J Psychiatry 1995; 10: 129s–35sCrossRef
67.
go back to reference Patat A, Le Go A, Foulhoux P. Dose-response relationship of vindeburnol based on spectral analysis of posturographic recordings. Eur J Clin Pharmacol 1985; 29: 455–9PubMedCrossRef Patat A, Le Go A, Foulhoux P. Dose-response relationship of vindeburnol based on spectral analysis of posturographic recordings. Eur J Clin Pharmacol 1985; 29: 455–9PubMedCrossRef
68.
go back to reference Allain H, Bentué-Ferrer D, Tarral A, et al. Effects on postural oscillation and memory functions of a single dose of zolpidem 5mg, zopiclone 3.75mg and lormetazepam 1mg in elderly healthy subjects: a randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol 2003; 59: 179–88PubMedCrossRef Allain H, Bentué-Ferrer D, Tarral A, et al. Effects on postural oscillation and memory functions of a single dose of zolpidem 5mg, zopiclone 3.75mg and lormetazepam 1mg in elderly healthy subjects: a randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol 2003; 59: 179–88PubMedCrossRef
69.
go back to reference Bizzo G, Guillet N, Patat A, et al. Specifications for building a vertical force platform designed for clinical stabilometry. Med Biol Eng Comput 1985; 23: 474–6PubMedCrossRef Bizzo G, Guillet N, Patat A, et al. Specifications for building a vertical force platform designed for clinical stabilometry. Med Biol Eng Comput 1985; 23: 474–6PubMedCrossRef
70.
go back to reference Kapteyn TS, Bles W, Njiokiktjien CJ, et al. Standardization in platform stabilometry being a part of posturography. Agressologie 1983; 24: 321–6PubMed Kapteyn TS, Bles W, Njiokiktjien CJ, et al. Standardization in platform stabilometry being a part of posturography. Agressologie 1983; 24: 321–6PubMed
71.
go back to reference Tada K, Sato Y, Sakai T, et al. Effects of zopiclone, triazolam and nitrazepam on standing steadiness. Neuropsychobiology 1994; 29: 17–22PubMedCrossRef Tada K, Sato Y, Sakai T, et al. Effects of zopiclone, triazolam and nitrazepam on standing steadiness. Neuropsychobiology 1994; 29: 17–22PubMedCrossRef
72.
go back to reference Robin DW, Hasan SS, Lichtenstein MJ, et al. Dose-related effect of triazolam on postural sway. Clin Pharmacol Ther 1991; 49: 581–8PubMedCrossRef Robin DW, Hasan SS, Lichtenstein MJ, et al. Dose-related effect of triazolam on postural sway. Clin Pharmacol Ther 1991; 49: 581–8PubMedCrossRef
73.
go back to reference Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. Sleep 2000; 23Suppl. 1: 23–30 Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. Sleep 2000; 23Suppl. 1: 23–30
74.
go back to reference Hindmarch I, Patat A, Stanley N, et al. Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. Hum Psychopharmacol Clin Exp 2001; 16: 159–67CrossRef Hindmarch I, Patat A, Stanley N, et al. Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. Hum Psychopharmacol Clin Exp 2001; 16: 159–67CrossRef
75.
go back to reference Vermeeren A, Danjou PH, O’Hanlon JR. Residual effects of evening and middle of the night administration of zaleplon 10 and 20mg on memory and actual driving. Hum Psychopharmacol Clin Exp 1998; 13: S98–S107CrossRef Vermeeren A, Danjou PH, O’Hanlon JR. Residual effects of evening and middle of the night administration of zaleplon 10 and 20mg on memory and actual driving. Hum Psychopharmacol Clin Exp 1998; 13: S98–S107CrossRef
76.
go back to reference Roehrs T, Rosenthal L, Koshorek BA, et al. Effects of zaleplon or triazolam with or without ethanol on human performance. Sleep Med 2001; 2: 323–32PubMedCrossRef Roehrs T, Rosenthal L, Koshorek BA, et al. Effects of zaleplon or triazolam with or without ethanol on human performance. Sleep Med 2001; 2: 323–32PubMedCrossRef
77.
go back to reference Parks V, Leister C, Patat A, et al. Effects of ethanol at a blood alcohol concentration of 0.4 g/L on actual driving and memory. Eur Neuropsychopharmacol 2002; 12Suppl. 3: S432–3CrossRef Parks V, Leister C, Patat A, et al. Effects of ethanol at a blood alcohol concentration of 0.4 g/L on actual driving and memory. Eur Neuropsychopharmacol 2002; 12Suppl. 3: S432–3CrossRef
78.
go back to reference Ray WA, Thapa PW, Gideon P. Benzodiazepines and the risks of falls in nursing home residents. Am J Geriatr Soc 2000; 48: 682–5 Ray WA, Thapa PW, Gideon P. Benzodiazepines and the risks of falls in nursing home residents. Am J Geriatr Soc 2000; 48: 682–5
79.
go back to reference Ray WA. Psychotropic drugs and injuries among the elderly: a review. J Clin Psychopharmacol 1992; 12: 386–96PubMed Ray WA. Psychotropic drugs and injuries among the elderly: a review. J Clin Psychopharmacol 1992; 12: 386–96PubMed
80.
go back to reference Avidan AY, Fries BE, James ML, et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 2005; 53: 955–62PubMedCrossRef Avidan AY, Fries BE, James ML, et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 2005; 53: 955–62PubMedCrossRef
81.
go back to reference Stevens M, D’Arcy J, Holman C, et al. Preventing falls in older people: impact of an intervention to reduce environmental hazards in the home. J Am Geriatr Soc 2001; 49: 1442–7PubMedCrossRef Stevens M, D’Arcy J, Holman C, et al. Preventing falls in older people: impact of an intervention to reduce environmental hazards in the home. J Am Geriatr Soc 2001; 49: 1442–7PubMedCrossRef
82.
go back to reference Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003; 26: 261–82PubMedCrossRef Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003; 26: 261–82PubMedCrossRef
83.
go back to reference Damgen K, Luddens H. Zaleplon displays a selectivity to re-combinant GABAA receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 1999; 25: 139–45CrossRef Damgen K, Luddens H. Zaleplon displays a selectivity to re-combinant GABAA receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 1999; 25: 139–45CrossRef
84.
go back to reference Crestani F, Martin JR, Molher H, et al. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 2000; 131: 1251–4PubMedCrossRef Crestani F, Martin JR, Molher H, et al. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 2000; 131: 1251–4PubMedCrossRef
85.
go back to reference Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA A receptor subtypes. Eur J Pharmacol 2002; 451: 103–10PubMedCrossRef Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA A receptor subtypes. Eur J Pharmacol 2002; 451: 103–10PubMedCrossRef
86.
go back to reference Verster JC, Veldhuijzen DS, Patat A, et al. Hypnotics and driving safety: not half-life but dosage determines the magnitude of driving impairment: meta-analyses of randomized controlled clinical trials applying on-the-road driving test. N Engl J Med. In press Verster JC, Veldhuijzen DS, Patat A, et al. Hypnotics and driving safety: not half-life but dosage determines the magnitude of driving impairment: meta-analyses of randomized controlled clinical trials applying on-the-road driving test. N Engl J Med. In press
87.
go back to reference Camus M, Pailhous J, Bonnard M. Cognitive tuning of corticospinal excitability during human gait: adaptation to the phase. Eur J Neurosci 2004; 20: 1101–7PubMedCrossRef Camus M, Pailhous J, Bonnard M. Cognitive tuning of corticospinal excitability during human gait: adaptation to the phase. Eur J Neurosci 2004; 20: 1101–7PubMedCrossRef
88.
go back to reference Mattila MJ, Vanakovski J, Kalska H, et al. Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol Biochem Behav 1998; 59: 917–23PubMedCrossRef Mattila MJ, Vanakovski J, Kalska H, et al. Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol Biochem Behav 1998; 59: 917–23PubMedCrossRef
89.
go back to reference Vermeeren A. Residual effects of hypnotics epidemiology and clinical implications. CNS Drugs 2004; 18: 297–328PubMedCrossRef Vermeeren A. Residual effects of hypnotics epidemiology and clinical implications. CNS Drugs 2004; 18: 297–328PubMedCrossRef
90.
go back to reference Heckman GA, Papaioannou A, Gagnon M, et al. The effect of cholinesterase inhibitors on the risk of falls and injuries in patients with mild to moderate Alzheimer’s dementia (protocol for a Cochrane review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 2002 Heckman GA, Papaioannou A, Gagnon M, et al. The effect of cholinesterase inhibitors on the risk of falls and injuries in patients with mild to moderate Alzheimer’s dementia (protocol for a Cochrane review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 2002
91.
go back to reference Maeker E, Bombois S, Pardessus V, et al. Troubles cognitifs et chutes: l’expérience de la consultation multidisciplinaire de la chute de Lille [in French]. Rev Neurol (Paris) 2005; 161: 419–26CrossRef Maeker E, Bombois S, Pardessus V, et al. Troubles cognitifs et chutes: l’expérience de la consultation multidisciplinaire de la chute de Lille [in French]. Rev Neurol (Paris) 2005; 161: 419–26CrossRef
92.
go back to reference Hajak G, Cluydts R, Allain H, et al. The challenge of chronic insomnia: is non nightly hypnotic treatment a feasible alternative. Eur Psychiatry 2003; 18: 201–8PubMedCrossRef Hajak G, Cluydts R, Allain H, et al. The challenge of chronic insomnia: is non nightly hypnotic treatment a feasible alternative. Eur Psychiatry 2003; 18: 201–8PubMedCrossRef
93.
go back to reference Estivill E, Bove A, Garcia-Borreguero D, et al. Consensus on drug treatment, definition and diagnosis for insomnia. Clin Drug Invest 2003; 23: 351–85CrossRef Estivill E, Bove A, Garcia-Borreguero D, et al. Consensus on drug treatment, definition and diagnosis for insomnia. Clin Drug Invest 2003; 23: 351–85CrossRef
94.
go back to reference Avidan AY. Sleep changes and disorders in the elderly patient. Curr Neurol Neurosci Rep 2002; 2: 178–85PubMedCrossRef Avidan AY. Sleep changes and disorders in the elderly patient. Curr Neurol Neurosci Rep 2002; 2: 178–85PubMedCrossRef
95.
go back to reference Mayor S. NICE issues guidelines to prevent falls in elderly people. BMJ 2004; 329: 1258 Mayor S. NICE issues guidelines to prevent falls in elderly people. BMJ 2004; 329: 1258
96.
go back to reference Marks R, Allegrante JP, Mackenzie CR, et al. Hip fractures among the elderly: causes, consequences and control. Ageing Res Rev 2003; 2: 57–93PubMedCrossRef Marks R, Allegrante JP, Mackenzie CR, et al. Hip fractures among the elderly: causes, consequences and control. Ageing Res Rev 2003; 2: 57–93PubMedCrossRef
97.
go back to reference Dundar Y, Dodd S, Strobl J, et al. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and metaanalysis. Hum Psychopharmacol Clin Exp 2004; 19: 305–32CrossRef Dundar Y, Dodd S, Strobl J, et al. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and metaanalysis. Hum Psychopharmacol Clin Exp 2004; 19: 305–32CrossRef
98.
go back to reference Elwyn G, Gwyn R. Stories we hear and stories we tell: analysing talk in clinical practice. BMJ 2005; 318: 186–8CrossRef Elwyn G, Gwyn R. Stories we hear and stories we tell: analysing talk in clinical practice. BMJ 2005; 318: 186–8CrossRef
99.
go back to reference Allain H, Bentué-Ferrer D, Le Breton S, et al. Preference of insomniac patients between a single dose of zolpidem 10mg versus zaleplon 10mg. Hum Psychopharmacol Clin Exp 2003; 18: 369–74CrossRef Allain H, Bentué-Ferrer D, Le Breton S, et al. Preference of insomniac patients between a single dose of zolpidem 10mg versus zaleplon 10mg. Hum Psychopharmacol Clin Exp 2003; 18: 369–74CrossRef
100.
go back to reference Sullivan SK, Petroski RE, Verge G, et al. Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedativehypnotic, with the GABAA receptor. J Pharmacol Exp Ther 2004; 311: 537–46PubMedCrossRef Sullivan SK, Petroski RE, Verge G, et al. Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedativehypnotic, with the GABAA receptor. J Pharmacol Exp Ther 2004; 311: 537–46PubMedCrossRef
101.
go back to reference Kato K, Hirri K, Nischiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48: 301–10PubMedCrossRef Kato K, Hirri K, Nischiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48: 301–10PubMedCrossRef
Metadata
Title
Postural Instability and Consequent Falls and Hip Fractures Associated with Use of Hypnotics in the Elderly
A Comparative Review
Authors
Professor Hervé Allain
Danièle Bentué-Ferrer
Elisabeth Polard
Yvette Akwa
Alain Patat
Publication date
01-09-2005
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 9/2005
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200522090-00004

Other articles of this Issue 9/2005

Drugs & Aging 9/2005 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.